Complement involvement in kidney diseases: From physiopathology to therapeutical targeting

doi:10.5527/wjn.v4.i2.169

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

(420)

(355)

(0)

(13)

(9963)

(19)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Nephrol. May 6, 2015; 4(2): 169-184
Published online May 6, 2015. doi: 10.5527/wjn.v4.i2.169

Table 2 Some of the molecules aimed to target complement, phase of the trial and renal diseases related

Compound name	Complement target	Compound class	Phase/indication
C1 inhibitor (Berinert)	C1r, C1s, MASP1, MASP2	Regulator	P 1/2 transplant
Cp40, AMY 101			PC transplant , aHUS, DDD
sCR1, CDX-1135	C3 conv, C4b, C3b	Regulator	P 1 DDD
Mirococept, APT070	C3 conv, C4b, C3b	Regulator	P 1/2 transplant
Eculizumab	C5	Ab	P 4 aHUS, P 2/3 STEC-HUS, P 2 ANCA vasculitis, P 1 transplant
Mubodina	C5	Ab	PC aHUS, DDD
Ergidina	C5	Ab	PC transplant
CCX168	C5aR	Small molecule	P 2 ANCA vasculitis
ADC-1004	C5aR	Protein	PC transplant

MASP1: Mannan-binding lectin-associated serine protease; P: Phase; PC: Preclinical; aHUS: Atypical hemolytic uremic syndrome; DDD: Dense deposit disease; sCR1: Soluble complement receptor 1; Ab: Antibodies; STEC-HUS: Shiga toxin producing Escherichia Coli-hemolytic uremic syndrome.

Full Size Table

Citation: Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184
URL: https://www.wjgnet.com/2220-6124/full/v4/i2/169.htm
DOI: https://dx.doi.org/10.5527/wjn.v4.i2.169

Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.